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Abstract 
Previous findings in rats and in human vegetarians suggest that the plasma carnitine 
concentration and/or carnitine ingestion may influence the renal reabsorption of 
carnitine. We tested this hypothesis in rats with secondary carnitine deficiency following 
treatment with N-trimethyl-hydrazine-3-propionate (THP) for 2 weeks and rats treated 
with excess L-carnitine for 2 weeks. Compared to untreated control rats, treatment with 
THP was associated with an approximately 70% decrease in plasma carnitine and with 
a 74% decrease in the skeletal muscle carnitine content. In contrast, treatment with L-
carnitine increased plasma carnitine levels by 80% and the skeletal muscle carnitine 
content by 50%. Treatment with L-carnitine affected neither the activity of carnitine 
transport into isolated renal brush border membrane vesicles, nor renal mRNA 
expression of the carnitine transporter OCTN2. In contrast, in carnitine deficient rats, 
carnitine transport into isolated brush border membrane vesicles was increased 1.9-fold 
compared to untreated control rats. Similarly, renal mRNA expression of OCTN2 
increased by a factor of 1.7 in carnitine deficient rats, whereas OCTN2 mRNA 
expression remained unchanged in gut, liver or skeletal muscle. Our study supports the 
hypothesis that a decrease in the carnitine plasma and/or glomerular filtrate 
concentration increases renal expression and activity of OCTN2. 
 
Key words: renal carnitine reabsorption; OCTN2; secondary carnitine deficiency; N-
trimethyl-hydrazine-3-propionate 
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1. Introduction 
Carnitine is essential for the transport of activated long chain fatty acids into the 
mitochondrial matrix, where they can be metabolized by β-oxidation (Bremer, 1983; 
Fritz, 1955). Beside its role in fatty acid transport, carnitine is also important as a buffer 
of the CoA pool (Brass and Hoppel, 1980; Friolet et al., 1994) and for the export of 
potentially toxic acyl-groups from cells (Brass and Hoppel, 1980; Vernez et al., 2006). 
Loss of carnitine from the body is minimized by the Na+-dependent high affinity 
carnitine transporter OCTN2 (SLC22A5), which is primarily responsible for reabsorption 
of filtered carnitine in the kidney (Nezu et al., 1999; Stieger et al., 1995; Tamai et al., 
1998). In comparison to OCTN2, OCTN1 (SLC22A4), which is also expressed on the 
luminal side of proximal renal tubular cells (Koepsell et al., 2007), reveals lower 
transport activities for carnitine (Yabuuchi et al., 1999). In primary systemic carnitine 
deficiency (CDSP, OMIM 212140), caused by mutations in the SLC22A5 gene 
encoding OCTN2, proximal tubular reabsorption of carnitine is impaired, indicating that 
OCTN2 is the most important transporter for renal carnitine reabsorption (Nezu et al., 
1999; Rahbeeni et al., 2002; Seth et al., 1999; Wang et al., 1999). Clinical findings in 
patients with primary carnitine deficiency, in particular myopathy, cardiomyopathy, 
hepatomegaly and failure to thrive, result from low tissue carnitine levels (Nezu et al., 
1999; Treem et al., 1988).  
Considering the physiological roles of carnitine, it is not surprising that the regulation of 
OCTN2 expression is related to fatty acid metabolism. Activation of PPAR alpha is 
associated with an increase mRNA expression of OCTN2 in liver, skeletal muscle, gut 
and kidney from pigs (Ringseis et al., 2008), rats (Maeda et al., 2008; Ringseis et al., 
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2007) and mice (Hirai et al., 2007; Koch et al., 2008; van Vlies et al., 2007). In humans, 
treatment with insulin is associated with an increase in carnitine transport into and 
expression of OCTN2 in skeletal muscle (Stephens et al., 2006). In kidney and 
intestine, targeting of OCTN2 to the brush border membrane is dependent on proteins 
with PDZ domains such as PDZK1 (Kato et al., 2005; Koepsell et al., 2007), which also 
affects the activity of OCTN2. 
Regarding renal transport of carnitine, the plasma carnitine concentration, which 
represents a surrogate of the carnitine concentration in the glomerular filtrate, may 
influence the activity of OCTN2. Rebouche and Mack reported that the sodium-
dependent transport of L-carnitine into brush border membrane vesicles from rat kidney 
is decreased after treatment of the rats with L-carnitine (Rebouche and Mack, 1984). In 
vegetarians, the plasma carnitine concentrations are reduced and renal clearance of 
carnitine is decreased compared to omnivores (Lombard et al., 1989), suggesting that 
low carnitine plasma concentrations are associated with increased renal activity of 
OCTN2. 
The aim of the current study was to find out whether the plasma carnitine concentration 
can influence activity and expression of the renal OCTN2 in rats. For this purpose, 
tissue mRNA expression and proximal tubular function of OCTN2 were studied in rats 
treated with excess carnitine, rats with secondary carnitine deficiency induced by 
treatment with N-trimethyl-hydrazine-3-propionate (THP) and untreated control rats. 
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2. Materials and Methods 
2.1. Reagents 
L-[3H]-carnitine hydrochloride, D-[3H]-glucose and L-[3H]-alanine were obtained from 
Amersham-Pharmacia Biotech (Little Chalfont, Buckinghamshire, England). L-carnitine 
was from Fluka; all other chemicals were from Sigma. 
 
2.2. Treatment of the animals and study protocol 
The study had been reviewed and accepted by the Animal Ethics Committee of the 
Canton of Basel-Stadt. Male, 3 weeks old Sprague Dawley rats (45±4 g) were 
purchased from Harlan Teklad (Horst, The Netherlands) and housed in groups of two 
with free access to food and water. The specific treatments were started after an 
acclimation period of 14 days. Control rats (Control; n=6) were treated with ground-up, 
commercial rat food for 2 weeks. Rats treated with carnitine (Carnitine; n=6) received 
50 mg L-carnitine per 100 g body weight per day for 2 weeks via the ground-up food. 
Rats treated with THP (THP rats; n=6) were treated with 20 mg per 100 g body weight 
THP per day via the ground-up food for 2 weeks (Spaniol et al., 2001). 
During the last 24 hours of the respective treatment, rats were housed in metabolic 
cages for urine collection. The volume was registered and a sample frozen at –70°C. At 
the end of the treatment period, rats were killed by CO2 narcosis followed by 
decapitation. Blood was obtained from the trunk into a heparinized beaker, and pieces 
of liver, skeletal muscle (quadriceps femoris) and gut (close to stomach) were removed 
and quickly frozen in liquid nitrogen. Kidneys were removed, a small piece of one 
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kidney was frozen in liquid nitrogen and the remainder used for the preparation of 
proximal tubular brush border membrane vesicles as described below. 
 
2.3. Isolation of proximal tubular brush border membrane vesicles 
Rat kidney brush border membrane vesicles were prepared by an EGTA/magnesium 
precipitation method as described previously in detail (Biber et al., 1981; Stieger et al., 
1995). After the final centrifugation step, membrane vesicles were taken up in 400 mM 
Hepes/Tris, pH 7.4, dispersed using a syringe with a fine needle and used immediately 
for transport experiments. Protein determinations were performed by the Lowry method 
after protein precipitation with trichloroacetic acid (Bensadoun and Weinstein, 1976). 
 
2.4. Transport of L-carnitine into proximal tubular membrane vesicles 
Transport experiments were performed with a rapid filtration technique using cellulose 
nitrate filters (0.65 mm pore size from Sartorius, Göttingen, Germany) as described 
previously (Stieger et al., 1983). Incubations contained (final concentrations, sodium 
gradient) 100 mM NaCl, L-carnitine as described in the Figures and Tables, 0.2 µCi L-
[3H]-carnitine, 200 mM mannitol and 20 mM Hepes/Tris, pH 7.4. Incubations containing 
a choline gradient were composed of 100 mM choline chloride instead of NaCl, 
otherwise the composition was identical with the incubations containing the sodium 
gradient. Transport was started by adding 15 µl of membrane suspension 
(approximately 10 µg protein) to 30 µl of preheated incubation medium (37°C). Since 
pilot studies had shown that transport was linear up to 5 minutes, the kinetic 
experiments were performed after an incubation time of 2 minutes. At this time point, 30 
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µl of the incubation suspension were withdrawn, diluted with 5 ml ice-cold stop solution 
(100 mM choline chloride, 1 mM L-carnitine, 200 mM mannitol and 20 mM Hepes/Tris, 
pH 7.4), filtered as described above and the filter rewashed twice with ice-cold stop 
solution. The filters were solubilized with 2ml of 1% Triton X-100 (w/v) and the 
radioactivity was counted after addition of 5ml scintillation fluid (Ultima-goldTM, Packard 
Bioscience, Zürich. Switzerland). 
The Na+-dependent L-carnitine uptake was obtained as the difference between total 
carnitine uptake (carnitine uptake determined in the presence of the sodium uptake 
buffer) and Na+-independent carnitine uptake (carnitine uptake in the presence of the 
choline buffer). 
In pilot experiments, the transport of D-glucose (final concentration 50 µM) and L-
alanine (final concentration 50 µM) into brush border membrane vesicles was 
determined using the same conditions as described above for L-carnitine. 
 
2.5. Carnitine and acylcarnitines in plasma, urine and tissues 
The carnitine concentrations in plasma, skeletal muscle and urine were determined 
radioenzymatically using the method described by Brass and Hoppel (Brass and 
Hoppel, 1978). Plasma and muscle samples were first treated with perchloric acid (final 
concentration 3%), resulting in a supernatant and a pellet. Analysis of the supernatant 
yielded the free carnitine concentration, and, after alkaline hydrolysis, the total acid 
soluble carnitine concentration. The pellet was used to determine the long-chain 
acylcarnitine concentration (acyl group chain length ≥10 carbons) after alkaline 
hydrolysis. The short-chain acylcarnitine concentration (acyl group chain length <10 
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carbons) was calculated as the difference between the total acid soluble and the free 
carnitine concentration. The total carnitine concentration was calculated as the sum of 
the total acid soluble and long-chain acylcarnitine concentration. 
The creatinine concentrations in plasma and urine were determined by the hospital-
based clinical chemistry laboratory using Jaffe’s method. 
 
2.6. Expression of OCTN2 mRNA in rat tissues and in 293-EBNA cells 
From frozen tissues, total RNA was obtained using QIAGEN mini-prep columns 
(Qiagen, Hombrechtikon, Switzerland) as described previously (Spaniol et al., 2003). 
293-EBNA cells (ATCC, Molsheim, France) were grown to confluency and then 
exposed to 50 or 150 µmol/l L-carnitine or THP for 8 or 24 hours. Total RNA was 
isolated using RNeasy® as described by the manufacturer (Qiagen, Hombrechtikon, 
Switzerland). The quality of the total RNA samples was analysed using Agilent's Pico-
Chips (Agilent Technologies Schweiz, Basel, Switzerland). Superscript TM II together 
with Oligo (dT) and Random Hexamer primers (Invitrogen, Basel, Switzerland) were 
used for reverse transcription of 2 µg total RNA. 
The real-time PCR was carried out in a total reaction volume of 10 µl containing the 
TaqMan mastermix, cDNA corresponding to 10 ng total RNA as described previously 
(Spaniol et al., 2001). The primers and probe were: forward primer 5’-
C(A/C)TATGTGTTGGCCTGGCTG-3’; reverse primer 5’-
AACTTGCCCACCATCACCAG-3’; probe: 5’-FAM-
CTCTTCCTGGGTGGCAGTGTCCTTCTCT-TAMRA-3’. The reactions were carried out 
on an ABI Prism 7900 sequence detection system (Applied Biosystems, Rotkreuz, 
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Switzerland). Thermocycling conditions used were: 95°C for 10 minutes followed by 40 
cycles each of 95°C for 15 seconds and 60°C for 60 seconds. 
Quantification of OCTN2 tissue and cellular mRNA levels was performed with GAPDH 
or 18S rRNA as an endogenous control as described previously (Spaniol et al., 2001). 
The results are expressed relative to the values obtained in control rats or untreated 
cells, which were set at 100%. 
 
2.7. Curve fitting and statistics 
Kinetic parameters of the sodium-dependent transport of L-carnitine into brush boarder 
membrane vesicles were calculated using SigmaPlot Version 11 (Scientific Solutions, 
Pully Lausanne, Switzerland). The sodium-dependent part of the transport activity (v) 
was fitted using Michaelis-Menten kinetics 
SK
SV
v
m
max
+
×
=  
where Vmax is the maximal velocity, S the L-carnitine concentration and Km the 
Michaelis-Menten constant. Every animal was analyzed individually and the statistics 
were performed using the constants (Vmax, Km) generated from each animal. 
Means were compared by one-way ANOVA followed by the Student-Newman-Keuls 
test in case of a significant finding. The SigmaStat version 3.5 software (Scientific 
Solutions, Pully Lausanne, Switzerland) was used for the statistical calculations. 
The renal clearances of carnitine and creatinine were determined by dividing the renal 
excretion of carnitine or creatinine over 24 hours by the respective plasma 
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concentrations. The excretion fraction of free and total carnitine was determined by 
dividing the respective renal clearance by the renal clearance of creatinine. 
Data are presented as mean±standard deviation (S.D.) if not stated otherwise. 
 
 
3. Results 
3.1. Characterization of the animals 
At the end of the respective treatment periods, body weights were 198±19 g for control 
rats, 195±19 g for rats treated with L-carnitine and 185 ± 30 g for rats treated with THP. 
The average food intake per rat and day was 22 g for control rats, 19 g for rats treated 
with L-carnitine and 18 g for rats treated with THP. 
Treatment with L-carnitine was associated with an increase in the plasma concentration 
(reaching 82% for total carnitine) and urinary excretion of free and short-chain 
acylcarnitines compared to control rats (Tables 1 and 2). In comparison, treatment with 
THP was associated with a significant decrease of plasma free, short-chain 
acylcarnitine and total carnitine (reaching 70% for total carnitine) and with an increase 
in renal carnitine excretion. Accordingly, compared to control rats, renal clearance of 
carnitine was significantly increased in rats treated with THP, but not in rats treated with 
L-carnitine. 
Similar to plasma, treatment with L-carnitine was associated with an increased skeletal 
muscle carnitine content (50% increase for total carnitine), whereas treatment with THP 
decreased the total carnitine content in skeletal muscle relative to control rats by 74% 
(Table 3). 
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3.2. Carnitine transport into rat kidney brush border membrane vesicles 
As shown Fig. 1 and Table 4, treatment with L-carnitine did not affect the sodium-
dependent transport of L-carnitine into brush border membrane vesicles. In contrast, 
treatment with THP was associated with a 1.9-fold increase in Vmax, but not in the Km, of 
L-carnitine transport into brush border membrane vesicles. 
In contrast to the transport of L-carnitine, treatment with L-carnitine or THP did not 
affect the transport of D-glucose or L-alanine (data not shown). 
 
3.3. OCTN2 mRNA expression in different tissues 
A shown in Fig. 2, treatment with L-carnitine was not associated with a change in 
OCTN2 mRNA expression in gut, liver, kidney or skeletal muscle compared to control 
rats. In contrast, treatment with THP was associated with a 74% increase in OCTN2 
mRNA expression in the kidney compared to control rats. However, treatment with THP 
did not affect OCTN2 mRNA expression in gut, liver or skeletal muscle compared to 
control rats. 
 
3.4. OCTN2 mRNA expression in 293-EBNA cells 
To investigate a possible direct effect of THP on OCTN2 mRNA expression in 
mammalian cells, the effect of L-carnitine and THP on OCTN2 mRNA expression was 
studied in cultured 293-EBNA cells, a human, proximal tubular cell line. Neither THP 
nor L-carnitine (both tested at 50 and 150 µmol/l for 8 and 24 hours) affected the mRNA 
expression of OCTN2 (data not shown). 
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4. Discussion 
The study was designed to test the hypothesis that the plasma carnitine concentration 
(a surrogate of the carnitine concentration in the glomerular filtrate) can influence the 
activity and expression of the renal OCTN2. Our results indicate that this is indeed the 
case. Rats with decreased plasma carnitine concentrations due to treatment with THP 
revealed a higher transport activity for L-carnitine into renal brush border membrane 
vesicles and a higher renal OCTN2 mRNA expression than control rats. 
Studies in vegetarians suggest that the plasma carnitine concentration is related to 
renal reabsorption of carnitine. Vegetarians show a decrease in the plasma carnitine 
concentration compared to healthy omnivores (Lombard et al., 1989; Rebouche et al., 
1993) and a decrease in renal clearance of carnitine, suggesting an increased activity 
of OCTN2 (Lombard et al., 1989), the renal transporter of carnitine (Nezu et al., 1999). 
In support of this interpretation, a study in patients treated with valproic acid has shown 
that the kidney increases the reabsorption of free carnitine during long-term treatment, 
counteracting carnitine deficiency associated with this drug (Stadler et al., 1999). Since 
endogenous biosynthesis of carnitine is limited (Bremer, 1983), this mechanism can be 
considered as a way to conserve the carnitine body stores in situations with limited 
exogenous supply of carnitine. Our studies are in agreement with the findings in 
vegetarians and indicate that in rats, renal mRNA expression and activity of OCTN2 are 
regulated by the carnitine concentration in plasma. Our study reveals also the possibility 
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that the carnitine concentration in the glomerular filtrate, which corresponds to the 
carnitine plasma concentration, regulates renal OCTN2 expression and activity. 
Caloric restriction has recently been proposed as one of the factors responsible for 
increased expression of OCTN2 mRNA in rat kidney (Luci et al., 2008). In our study, all 
rats had free access to food, ingested approximately the same amount of food and had 
a similar weight gain. These findings exclude the possibility that the observed increase 
in renal OCTN2 expression and activity in our study is due caloric restriction. 
Nevertheless, beside the carnitine plasma and/or glomerular filtrate concentration, 
caloric restriction represents an additional mechanism for the regulation of renal 
OCTN2 expression. 
Interestingly, mRNA expression of OCTN2 was affected by carnitine deficiency only in 
the kidney, but not in the other organs investigated. While the exposure to carnitine of 
gut and possibly also liver was most probably not different between THP treated and 
control rats, skeletal muscle and kidney of THP treated rats had clearly a lower carnitine 
exposure than control rats. These findings indicate that the regulation of OCTN2 mRNA 
expression is different in skeletal muscle and in kidney. In support of this statement, 
glucose and insulin have been shown to increase OCTN2 mRNA expression and 
OCTN2 activity in skeletal muscle of humans (Stephens et al., 2006), but not in human 
kidney cell lines (L. Todesco and S. Krähenbühl, unpublished results). 
Studies by the group of Rebouche have previously suggested that renal transport of 
carnitine is decreased in rats (Rebouche and Mack, 1984) or human vegetarians 
(Rebouche et al., 1993) supplied with exogenous carnitine. In rats, Rebouche and Mack 
have shown that carnitine supplements decreases the transport activity for L-carnitine 
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into isolated proximal tubular brush border membrane vesicles (Rebouche and Mack, 
1984). Our data did not confirm these findings; exogenous carnitine affected neither 
transport of L-carnitine nor renal expression of OCTN2. This discrepancy may be 
explained by methodological differences between the studies. Rebouche and Mack 
measured the L-carnitine transport at higher concentrations than we did (up to 500 µM 
compared to 50 µM in our study) and found a Km value for carnitine of 55 µM 
(Rebouche and Mack, 1984). This value is considerably higher than the values 
obtained in the current and in other investigations, which are in the range of 10 µM 
(Stieger et al., 1995; Tamai et al., 1998). These discrepancies make a comparison of 
the two studies difficult. 
In human vegetarians, Rebouche et al. supplied only a limited amount of exogenous 
carnitine, which did not significantly affect the plasma carnitine concentration 
(Rebouche et al., 1993). Nevertheless, this small amount of exogenous carnitine was 
associated with an increase in renal carnitine clearance, suggesting that small amounts 
of exogenous carnitine can decrease the activity of the renal OCTN2. In the current 
study, carnitine supplementation was associated with an increase in the plasma 
carnitine concentration and renal excretion, but renal clearance of carnitine as well as 
renal OCTN2 mRNA expression and activity remained unchanged. The discrepancy 
between the studies may be explained by the amount of carnitine administered and/or 
by species differences. 
In conclusion, we provide evidence that a decrease in the carnitine plasma 
concentration is associated with increased renal mRNA expression and activity of 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
 
 
15
OCTN2, whereas OCTN2 expression is not affected in other organs. Further studies 
are needed to find out the precise molecular mechanism responsible for these findings. 
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Table 1 
 
Plasma carnitine concentrations. Rats were treated with L-carnitine (50 mg/kg body 
weight for 2 weeks; Carnitine) or THP (20 mg/kg body weight for 2 weeks; THP), or 
were age-matched control rats (Control). At the end of the treatment period, rats were 
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killed and the carnitine concentration in plasma was determined as described in 
Methods. Data are presented as mean±S.D., units are µmol/l. 
 
 Control 
(n=6) 
Carnitine (n=6) THP 
(n=6) 
Free carnitine 22.2±4.9 42.0±4.3* 5.9±1.6a,b 
Short-chain 
acylcarnitine 
39.3±17.9 71.0±9.0* 10.9±1.9a,b 
Long-chain 
acylcarnitine 
2.8±0.6 3.7±0.8 2.4±0.8b 
Total carnitine 64.2±17.7 117±10* 19.2±3.1a,b 
aP<0.05 vs. control 
bP<0.05 vs. carnitine 
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Table 2 
Urinary carnitine excretion. Rats were treated with L-carnitine (50 mg/kg body weight for 
2 weeks; Carnitine) or THP (20 mg/kg body weight for 2 weeks; THP), or were age-
matched control rats. At the end of the treatment period, rats were killed and the 
carnitine concentration in urine as well as the creatinine concentrations in urine and 
plasma were determined as described in Methods. Calculations were performed as 
described in Methods. Data are presented as mean±S.D.. 
 
 Control Carnitine THP 
Free carnitine (µmol/24 h) 0.36±0.21 0.85±0.25a 0.54±0.25 
Short-chain acylcarnitine 
(µmol/24 h) 
0.12±0.10 0.67±0.21a 0.15±0.09b 
Total carnitine (µmol/24 h) 0.48±0.16 1.52±0.46a 0.69±0.28b 
Free carnitine clearance 
(ml/24h) 
17.0±11.8 20.5±6.4 96.0±46.8a,b 
Total carnitine clearance 
(ml/24h) 
8.6±4.2 13.7±5.1 41.6±16.6a,b 
Excretion fraction free 
carnitine (% of filtered load) 
0.48±0.30 0.61±0.20 2.73±1.37a,b 
Excretion fraction total 
carnitine (% of filtered load) 
0.25±0.11 0.41±0.15 1.18±0.46a,b 
aP<0.05 vs. control 
bP<0.05 vs. carnitine 
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Table 3 
Skeletal muscle carnitine content. Rats were treated with L-carnitine (50 mg/kg body 
weight for 2 weeks; Carnitine) or THP (20 mg/kg body weight for 2 weeks; THP), or 
were age-matched control rats. At the end of the treatment period, rats were killed and 
the carnitine content in skeletal muscle was determined as described in Methods. Data 
are presented as mean±S.D., units are µmol/g dry weight. 
 
 Control Carnitine THP 
Free carnitine 5.64±0.42 7.74±2.69 1.26±0.39a,b 
Short-chain 
acylcarnitine 
1.80±1.10 4.10±2.84 0.52±0.20a,b 
Long-chain 
acylcarnitine 
0.81±0.23 0.57±0.13 0.39±0.12a,b 
Total carnitine 8.25±0.83 12.4±3.0a 2.17±0.23a,b 
aP<0.05 vs. control 
bP<0.05 vs. carnitine 
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Table 4 
Kinetic constants of the sodium-dependent transport of L-carnitine into rat brush border 
membrane vesicles. Rats were treated with L-carnitine (50 mg/kg body weight for 2 
weeks; Carnitine) or THP (2 weeks with 20 mg/kg body weight; THP) or were age-
matched control rats. The sodium-dependent part of the transport activity was 
calculated as the difference between the transport activities in the presence of a 
sodium minus the activity in the presence of a choline gradient. The resulting transport 
activities could be described by Michaelis-Menten kinetics and were analyzed by linear 
regression as described in Methods. Results are presented as mean±S.D. from n=6 
independent experiments. 
 
 Vmax  
(pmol x min-1 x mg protein-1) 
Km  
(µmol/l) 
Control 69.6±20.0 17.8±4.5 
Carnitine-treated 63.5±19.4 15.4±6.6 
THP-treated 131±25a,b 22.2±10.9 
aP<0.05 vs. control 
bP<0.05 vs. carnitine 
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Figure legends 
Fig. 1 
Transport of L-carnitine into rat kidney brush border membrane vesicles. Isolation of 
vesicles and transport experiments are described in the Method section. Activities were 
determined in the presence of a sodium gradient (sodium) or of a choline gradient 
(choline). The sodium-dependent portion of L-carnitine transport was obtained by 
subtraction of the transport activity in the presence of the sodium minus the choline 
gradient (sodium-choline). Rats treated with THP have higher sodium-dependent 
transport activities compared to control rats (control) or rats treated with carnitine 
(carnitine substitution). Numerical values are given in Table 4. Data are means±S.D. 
from n=6 independent measurements. 
 
Fig. 2 
OCTN2 mRNA expression in different organs. Rats were untreated controls (Control) or 
treated with L-carnitine (Carnitine) or with THP (THP) as described in Methods. OCTN2 
mRNA expression was determined by rt PCR as described in Methods using GAPDH 
mRNA as a reference. With the exception of an increase in the renal OCTN2 mRNA 
expression in rats treated with THP, there were no differences in the organ-specific 
OCTN2 mRNA expression. 
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